Sept 10 (Reuters) - Viridian Therapeutics ( VRDN ) said

on Tuesday its experimental drug to treat patients with thyroid

eye disease significantly reduced bulging of the eye in a

late-stage study.

Shares of the company were up 6.4% in volatile premarket

trading.

Thyroid eye disease is an autoimmune disorder that causes

inflammation and damage to the tissues around the eye.

The drug, veligrotug, was generally well-tolerated with no

treatment-related serious side-effects, the company said.